Table 7.

Results of the univariate analysis of prognostic factors on locoregional and distant metastasis-free rates

		Locoregional-free rate			Distant metastasis-free rate
		Univariate analysis
Factor	Level (n)	HR1	95% CI	P-value	HR1	95% CI	P-value
Age	<50 (36)	1	0.4715–5.200	0.4604	1	0.330–3.278	0.9462
	≥50 (50)	1.566			1.040
Gender	Male (66)	1	0, infty	0.0303	1	0.116–2.417	0.4037
	Female (21)	Near 0			0.529
TNM primary	1 or 2 (52)	1	0.956–10.548	0.0464	1	0.492–4.735	0.4602
	3 or 4 (35)	3.175			1.527
TNM LN	0 or 1 (33)	1	0.761–15.925	0.0866	1	0, infty	0.0032
	2 or 3 (54)	3.482			Infty
Stage	IIB or III (58)	1	0.318–3.518	0.9262	1	1.390–15.379	0.0060
	IV (29)	1.058			4.624
WHO pathology	I (18)	1	0.099–0.986	0.0359	1	0, infty	0.0850
	II or III(69)	0.312			infty
PS	0 (73)	1	0.476–6.503	0.3902	1	0.252–5.250	0.8572
	1 or 2 (14)	1.760			1.149
RT dose primary	<70 (5)	1	0.064–1.340	0.0924	1	0, infty	0.4078
	≥70 (81)	0.293			infty
RT dose LN	<70 (21)	1	0.254–3.471	0.9255	1	0.356–7.407	0.5279
	≥70 (65)	0.940			1.622
Total dose of 5-FU	<12,000 (37)	1	0.135–1.349	0.1354	1	0.143–1.429	0.1657
	≥12,000 (50)	0.427			0.453
Total dose of CDDP	<300 (38)	1	0.210–2.024	0.4560	1	0.096–1.060	0.0490
≥300 (49)	0.652				0.319
OTT2	<87 (38)	1	0.126–1.474	0.1673	1	0.238–2.291	0.5986
	≥87 (47)	0.431			0.739

¹Hazard ratio.

²Overall treatment time.